IceCure Medical Stock-Based Compensation Growth & History (ICCM)
IceCure Medical's stock-based compensation was $1.4M for fiscal 2025.
View full IceCure Medical company overviewIceCure Medical annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.4M | $504,000 | +58.00% |
| 2024 | 2024-12-31 | $869,000 | −$441,000 | −33.66% |
| 2023 | 2023-12-31 | $1.3M | −$555,000 | −29.76% |
| 2022 | 2022-12-31 | $1.9M | $1.5M | +490.19% |
| 2021 | 2021-12-31 | $316,000 | $87,000 | +37.99% |
| 2020 | 2020-12-31 | $229,000 | −$143,000 | −38.44% |
| 2019 | 2019-12-31 | $372,000 | — | — |
IceCure Medical quarterly stock-based compensation
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $121,000 | −$49,000 | −28.82% |
| Q1 2026 | 2026-03-31 | $180,000 | $55,000 | +44.00% |
| Q4 2025 | 2025-12-31 | $271,000 | — | — |
| Q3 2025 | 2025-09-30 | $807,000 | — | — |
| Q2 2025 | 2025-06-30 | $170,000 | — | — |
| Q1 2025 | 2025-03-31 | $125,000 | — | — |
IceCure Medical stock-based compensation trends
Over the last five fiscal years, IceCure Medical's stock-based compensation increased from $229,000 to $1.4M, a change of $1.1M. The latest reported quarter, Q2 2026, shows $121,000.
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review IceCure Medical source filings ↗